Polyneuropathy

Hizentra Approved for Chronic Inflammatory Demyelinating Polyneuropathy

Hizentra Approved for Chronic Inflammatory Demyelinating Polyneuropathy

By

The PATH study demonstrated that the percentage of patients experiencing CIDP relapse or withdrawal for any other reason during SCIg treatment was significantly lower with Hizentra.

FDA Approves Demyelinating Polyneuropathy Treatment

FDA Approves Demyelinating Polyneuropathy Treatment

By

Privigen is a ready-to-use liquid intravenous immune globulin product stabilized with proline.

Long-Term Opioid Therapy Tied to Worse Outcomes in Polyneuropathy

Long-Term Opioid Therapy Tied to Worse Outcomes in Polyneuropathy

By

Most prescriptions for long-term opioid therapy were written by internal or family medicine physicians.

Sign Up for Free e-newsletters

CME Focus